Skip to main content
Donate

Differential Regulation of UBE3A Expression Following Neuronal Activation

Melinda M Peters, Aurelie Joly-Amado, Kevin R Nash, and Edwin J Weebert

Published November 1, 2025

https://doi.org/10.65856/RDCC3439

KEYWORDS: UBE3A, Angelman syndrome, paternal allele, maternal deletion, hippocampus, synaptic plasticity,neuronal activation, imprinting, Western blot, mouse model.

ABSTRACT: Angelman syndrome (AS) results from loss of the maternally inherited UBE3A allele, a neuronally imprinted gene essential for synaptic plasticity. While the maternal allele is active, the paternal copy is typically silenced, limiting therapeutic strategies. Here, we investigated activity-dependent regulation of maternal and paternal Ube3a using a YFP knock-in reporter that permits allele-specific protein quantification. In hippocampal slices, high-frequency stimulation and potassium depolarization triggered biphasic increases in UBE3A protein, with rapid early peaks and delayed secondary surges. Use of an in vivo, associative fear conditioning model revealed region-specific and allele-specific dynamics: hippocampal paternal Ube3a showed robust induction within 1–6 hours, maternal Ube3a exhibited sustained late upregulation, and parietal cortex expression from both alleles rose transiently within minutes. Prefrontal cortex responses were delayed, peaking at 6 hours. These results demonstrate that neuronal activity drives dynamic, allele-specific modulation of UBE3A across distinct cortical–hippocampal networks. Notably, paternal Ube3a can be transiently unsilenced following behavioral stimulation, revealing an untapped mechanism of regulation. This work highlights the potential to harness experience-dependent pathways to restore paternal UBE3A expression in AS, informing strategies for therapeutic reactivation.

DOWNLOAD PDF

FAST Angelman Syndrome News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.